ALLK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALLK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Allakos has the Momentum Rank of 1.
Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Allakos's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Allakos's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Allakos's Momentum Rank falls into.
Thank you for viewing the detailed overview of Allakos's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Harlan Baird Radford | officer: Chief Financial Officer | C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125 |
Graham Neil Murray Hamilton | director | 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520 |
Everett Rand Sutherland | director | 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Dolca Thomas | director | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Paul Edward Walker | director | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Daniel Janney | director | PO BOX 7414, JACKSON WY 83002 |
Amy L Ladd | director | INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086 |
Craig A. Paterson | officer: Chief Medical Officer | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Margaret Nell Fitzgerald | officer: General Counsel and Secretary | ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
Steven P James | director | C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
Adam Tomasi | officer: COO, CFO and Secretary | ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Robert Alexander | director, officer: President and CEO | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Rasmussen Henrik S Md | officer: Chief Medical Officer | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
John P Mckearn | director, 10 percent owner | 5820 NANCY DRIVE, SAN DIEGO CA 92121 |
Peter A Hudson | 10 percent owner | 701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By Marketwired • 02-10-2025
By Marketwired • 05-09-2024
By Marketwired • 06-25-2024
By Marketwired • 01-27-2025
By Marketwired • 10-10-2024
By GuruFocus Research • 11-13-2023
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 05-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.